cardiometabolic diseases
Novo Nordisk Strikes Major Deal with Deep Apple Therapeutics for Oral Cardiometabolic Medicines
Novo Nordisk; Deep Apple Therapeutics; cardiometabolic diseases; oral medicines; obesity; small molecule therapeutics; GPCR target; R&D collaboration; biotech partnership
Novo Nordisk and Septerna Forge $2.2B+ Collaboration on Oral Obesity and Diabetes Drugs
Novo Nordisk; Septerna; GPCR; oral drugs; obesity; type 2 diabetes; cardiometabolic diseases; GLP-1; GIP; glucagon receptors; small molecule therapies; collaboration; pharmaceuticals
Eli Lilly Expands Oncology and Metabolic Disease Portfolio with Strategic Partnerships
Eli Lilly, AdvanCell, OliX Pharmaceuticals, targeted alpha therapies, radiopharmaceuticals, MASH, cardiometabolic diseases, strategic collaborations
Eli Lilly Expands Pipeline with Strategic Deals in MASH and Cancer Therapies
Eli Lilly, OliX Pharmaceuticals, AdvanCell, MASH, targeted alpha therapies, radiopharmaceuticals, RNA interference, cardiometabolic diseases, cancer treatment
Novo Nordisk and Photys Therapeutics Collaborate on Novel Proximity-Based Therapeutics for Cardiometabolic Diseases
Novo Nordisk, Photys Therapeutics, Cardiometabolic diseases, Proximity-based therapeutics, PHICS technology, Research collaboration
AstraZeneca Advances in Obesity Market with ECC5004 Deal and Promising Clinical Data
AstraZeneca, obesity, ECC5004, GLP-1RA, cardiometabolic diseases, weight loss market
Rivus Pharmaceuticals Unveils Promising Phase 2a Results for HU6 in Obesity-Related Heart Failure Patients
HU6, Rivus Pharmaceuticals, obesity-related heart failure, fat-selective weight loss, controlled metabolic accelerators (CMAs), mitochondrial uncoupling, cardiometabolic diseases.
Novo Nordisk Partners with NanoVation in $600M Deal for Advanced Genetic Medicine Delivery
Novo Nordisk, NanoVation Therapeutics, Genetic Medicine, Lipid Nanoparticle (LNP) Technology, Cardiometabolic Diseases, Rare Genetic Disorders
Novo Nordisk and NanoVation Collaborate on $600M Genetic Medicine Deal for Rare and Cardiometabolic Diseases
Novo Nordisk, NanoVation, genetic medicine, lipid nanoparticle technology, cardiometabolic diseases, rare diseases, RNA delivery, base-editing therapies
Novo Nordisk and Korro Bio Collaborate on $530M RNA Editing Deal for Cardiometabolic Diseases
Novo Nordisk, Korro Bio, RNA editing, cardiometabolic diseases, genetic medicines, pharmaceutical partnerships